

Ovarian Cancer: Identifying and Managing Familial and Genetic Risk Committee meeting 12 – day 1

Date: 02.06.2023

Location: Virtually via Zoom

Minutes: FINAL

Committee members present:	
Alison Cameron (Chair)	(Present for notes 1 – 8)
Ranjit Manchanda (Topic adviser)	(Present for note 1 – 8) - absent 12:15-14:10
Rebecca Bowen	(Present for notes 1 – 8)
Adam Brentnall	(Present for notes 1 – 8)
Melanie Davies	(Present for notes 1 – 8) absent 14:00-14:30
Gareth Evans	(Present for notes 1 – 8) - absent 12:15-14:15
Judith Hayward	(Present for notes 1 – 8)
Glenn McCluggage	(Present for notes 1 – 8)
Tracie Miles	(Present for notes 1 – 8)
Fiona Robb	(Present for notes 1 – 8)
Adam Rosenthal	(Present for notes 1 – 7)
Lucy Side	(Present for notes 1 – 8)
Joanne Stanford	(Present for notes 1 – 8)
Vishakha Tripathi	(Present for notes 1 – 8)
Britta Stordal	(Present for notes 1 – 8)

In attendance:		
Angela Bennett	Director of Guidelines	(Present for notes 1 – 8)
Hayley Shaw	Project Manager	(Present for notes 1 – 8)
Nathan Bromham	Senior Systematic Reviewer	(Present for notes 1 – 8)
Laura Berg	Systematic Reviewer	(Present for notes 1 – 8)
Suhayl Kassam	Systematic Reviewer	(Present for notes 1 – 8)
Eric Slade	Senior Health Economist	(Present for notes 1 – 8)
Nick O'Callaghan Staples	Guideline Commissioning	(Present for notes 1 – 8)

	Manager	
Sarah Palombella	Senior Medical Editor	(Present for notes 1 – 8)

Apologies:	
Victoria Barber	Committee member (GP)
Mark Davies	Co-opted committee member (Consultant breast cancer specialist)
Kevin Monahan	Colorectal cancer specialist (co-opted member)
Davina Moses	Committee member (Psychologist)
Katharina Dworzynski	Guideline Lead
Steve Pilling	Clinical Advisor

1. Welcome, housekeeping, aims of the day and apologies.							
<p>The Chair welcomed the committee members and attendees to the first day of 12th meeting on Ovarian Cancer: Identifying and Managing Familial and Genetic Risk.</p> <p>The Chair informed the committee that apologies had been received. These are noted above.</p> <p>The Chair outlined the meeting objectives.</p>							
2. Confirmation of matter under discussion, and declarations of interest							
The Chair asked everyone to verbally declare any interests that have risen since the last meeting. New interests were declared as noted below.							
Name	Role	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Dr Britta Stordal	Committee member	Direct financial interest	EU Research Executive Agency – Grant Review – Occasional Contract Work reviewing grants	2010	06/06/2022	Ongoing	Declare and participate Agreed by GL June 2023 Rationale: Whilst this is a paid role there is no financial gain from this that is related to the committee work.
Dr Britta	Co-Opted	Direct non-Financial	Lay Member of UK	2023	06/06/2022	Ongoing	Declare and

Stordal	Member	Professional and Personal Interest	Systemic Anti-Cancer Therapy (SACT) Board		3	g	participate. Agreed by Guideline Lead June 2023 Rationale: This is not specific to the scope of the guideline.
Dr Britta Stordal	Co-Opted Member	Direct non-Financial Professional and Personal Interest	NICE - Specialist committee member for Diagnostics Advisory Committee - Tumour profiling tests to guide adjuvant chemotherapy decisions in lymph node-positive early breast cancer	2023	06/06/2023	Ongoing	Declare and participate. Agreed by Guideline Lead June 2023 Rationale: This is not specific to the scope of the guideline.
Dr Britta Stordal	Committee member	Direct non-financial professional and personal interest	Lay Member of Clinical Oncology Academic Committee – Royal College of Radiologists	2022	06/06/2023	Ongoing	Declare and participate. Agreed by GL June 2023 Rationale: This is not specific to the scope of the guideline.
Dr Britta Stordal	Committee member	Direct non-financial professional and personal interest	Vice Chair and Head of Science and Public Affairs Committee Breast Cancer UK	2021	06/06/2023	Ongoing	Declare and participate. Agreed by GL June 2023 Rationale: This is not specific to the scope of the guideline.
Dr Judith Hayward	GC Member	Financial Interest	Honorarium received (£250) from Pulse (Cogora) to deliver educational presentation entitled "Genomics for GPs: Current practice and future potential" which included	March 2023	02/05/2023	May 2023	Declare and participate. Agreed by Guideline Lead June 2023 Rationale: Cogora is a healthcare marketing agency that runs webinars for GPs. Whilst this interest is related to the scope, the presentation was

			slides regarding management of patients with a family history of ovarian cancer				educational and more focused on current practice. It did not include details of potential recommendations or discussions.
Dr Judith Hayward	GC Member	Non-Financial Professional and Personal Interest	Received travel expenses from Best Practice to deliver educational presentations within Best Practice London 2023. No expenses requested or received to deliver education presentation within Oncology Professional Practice 2023	March 2023	02/05/2023	March 2023	Declare and participate. Agreed by Guideline Lead June 2023 Rationale: This interest is not specific to the scope of the guideline.

3. Minutes of the last meeting

The Chair asked the committee to confirm the minutes of the last meeting, and the committee confirmed no changes were required.

4. Morning presentations

The Chair introduced Angela Bennett, Director of Guidelines, who led on finalising recommendations in the following sections of the guideline:

- 1.1 Organisation of services
- 1.2 Information and support
- 1.3 Assessing a person's risk of having a pathogenic variant associated with familial ovarian cancer.
- 1.4 Risk thresholds for genetic testing (family history, at risk populations and people with ovarian cancer).

5. Lay member forum

Lay members were given the opportunity to reflect and make any suggestions or comments to the other committee members.

6. Afternoon presentations

The Chair introduced Angela Bennett, Director of Guidelines, who led on finalising recommendations in the following sections of the guideline:

- 1.5 Gene panel testing
- 1.6 Assessing a person's risk of developing ovarian cancer.
- 1.7 Primary preventive medicines
- 1.9 Risk reducing surgery (factors to take into account, types, other considerations)
- 1.10 Pathological protocol for handling specimens from risk-reducing surgery
- 1.11 Hormone replacement therapy after risk reducing surgery

7. Questions and discussion

The committee discussed:

- The sections of the guidelines above and signed off the following sections: 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.10 and 1.11.
- Section 1.9 of the guideline and would be continued to be discussed in the second day of the 12th committee meeting.

8. Any other business and summary of actions

No other business was discussed.

The Chair closed the meeting at 16:30.

Ovarian Cancer: Identifying and Managing Familial and Genetic Risk Committee meeting 12 – day 2

Date: 08.06.2023

Location: Virtually via Zoom

Minutes: FINAL

Committee members present:

Alison Cameron (Chair)	(Present for notes 1 – 6)
Ranjit Manchanda (Topic Adviser)	(Present for notes 1 – 6)
Victoria Barber	(Present for notes 1 – 6)
Rebecca Bowen	(Present for notes 1 – 6)
Adam Brentnall	(Present for notes 1 – 6)
Melanie Davies	(Present for notes 1 – 6)
Gareth Evans	(Present for notes 1 – 6)
Judith Hayward	(Present for notes 1 – 6)
Tracie Miles	(Present for notes 1 – 6)
Davina Moses	(Present for notes 1 – 6)
Fiona Robb	(Present for notes 1 – 6)

Adam Rosenthal	(Present for notes 1 – 6)
Lucy Side	(Present for notes 1 – 6)
Joanne Stanford	(Present for notes 1 – 6)
Vishakha Tripathi	(Present for notes 2 – 6)
Mark Davies	(Present for notes 1 – 6)
Britta Stordal	(Present for notes 1 – 6)

In attendance:		
Katharina Dworzynski	Guideline Lead	(Present for notes 1 – 6)
Josh South	Senior Project Manager	(Present for notes 1 – 6)
Nathan Bromham	Senior Systematic Reviewer	(Present for notes 1 – 6)
Laura Berg	Systematic Reviewer	(Present for notes 1 – 6)
Suhayl Kassam	Systematic Reviewer	(Present for notes 1 – 6)
Eric Slade	Senior Health Economist	(Present for notes 1 – 6)
Daniel Davies (observing)	Project Manager	(Present for notes 1 – 6)
Neil Ryan	Clinical Fellow	(Present for notes 1 – 6)
Nick O’Callaghan Staples	Guideline Commissioning Manager	(Present for notes 1 – 6)
Sarah Palombella	Senior Medical Editor	(Present for notes 1 – 6)

Apologies:	
Glenn McCluggage	Committee member
Kevin Monahan	Co-opted member
Hayley Shaw	Project Manager
Steve Pilling	Clinical Adviser

1. Welcome, housekeeping, aims of the day and apologies
<p>The Chair welcomed the committee members and attendees to the second day of the 12th meeting on Ovarian Cancer: Identifying and Managing Familial and Genetic Risk.</p> <p>The Chair informed the committee that apologies had been received. These are noted above.</p> <p>The Chair outlined the meeting objectives.</p>

2. Confirmation of matter under discussion, and declarations of interest

The Chair asked everyone to verbally declare any interests that have risen since the last meeting. New interests were declared as noted below.

Name	Role	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Professor Gareth Evans	Topic Advisor	Direct non-financial professional and personal interest	<p>Guideline publication with ESMO. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.</p> <p>Sessa C, Balmaña J, Bober SL, Cardoso MJ, Colombo N, Curigliano G, Domchek SM, Evans DG, Fischerova D, Harbeck N, Kuhl C, Lemley B, Levy-Lahad E, Lambertini M, Ledermann JA, Loibl S, Phillips KA, Paluch-Shimon S; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org.</p> <p>Ann Oncol. 2023 Jan;34(1):33-47. doi: 10.1016/j.annonc.2022.10.004.</p>	January 2023	08.06.2023	January 2023	<p>Declare and participate</p> <p>Agreed by GL and Chair</p> <p>Rationale: Whilst this includes ovarian cancer it is broader than the scope with a focus on both breast and ovarian cancer. Decisions related to this guidance were based on consensus rather than reflect the committee members individual opinion.</p>

3. Morning presentations

The Chair introduced Katharina Dworzynski, Guideline Lead who led on finalising recommendations in the following sections of the guideline:

- 1.8 Ovarian cancer surveillance
- 1.9 Risk-reducing surgery (factors to take into account, types, other considerations)

4. Lay member forum
Lay members were given the opportunity to reflect and make any suggestions or comments to the other committee members.
5. Questions and discussion
The committee discussed: <ul style="list-style-type: none">• The sections of the guideline outlined above and signed off these sections.
6. Any other business and summary of actions
Katharina Dworzynski summarised the actions No other business was discussed. The Chair closed the meeting at 11:20

Date of next meeting: 14th November & 16th November 2023

Location of next meeting: 14th November – in person at NICE Offices London
16th November – virtual via Zoom.